Photo by neom from unsplash
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed… Click to show full abstract
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma Maria Gavriatopoulou, Evangelos Terpos , Ioannis Ntanasis-Stathopoulos , Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Athanasios Papatheodorou, Nikolaos Kanellias, Magdalini Migkou, Despina Fotiou, Ioanna Dialoupi, Maria Roussou, Nikoletta-Aikaterini Kokkali, Efstathios Kastritis 1 and Meletios A. Dimopoulos
Journal Title: Blood Cancer Journal
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!